Department of Pediatrics and Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, Children's Hospital Los Angeles, 4650 Sunset Blvd, Mailstop #57, Los Angeles, CA 90027, USA.
Curr Mol Med. 2013 Jun;13(5):751-6. doi: 10.2174/1566524011313050006.
MicroRNAs (miRNAs) are de-regulated in cancer versus the normal tissue counterpart and actively participate in human carcinogenesis. Among the genes whose expression is under their control there are both oncogenes and tumor suppressor genes, revealing that it is not only limiting but simply wrong to assign them a function just as oncogenes or as tumor suppressor genes. In addition to primary tumors, miRNAs can be detected in almost all human body fluids and effectively help to diagnose cancer and to prognosticate clinical outcome and response to treatment of tumors. The advent of miRNA mimic and miRNA silencing molecules has allowed to modulate miRNA expression in tumors, showing that miRNAs can be effectively used as therapeutic agents. This review will focus on those findings that have provided the rationale for the use of miRNAs as patient "tailored" anti-cancer agents.
微小 RNA（miRNA）在癌症与正常组织对照中失调，并积极参与人类肿瘤发生。在受其调控的基因中，既有癌基因又有肿瘤抑制基因，这表明将它们仅仅归为癌基因或肿瘤抑制基因的功能不仅是有限的，而且是错误的。除了原发性肿瘤，miRNA 几乎可以在所有人体体液中检测到，有效地帮助诊断癌症，并预测肿瘤的临床结果和对治疗的反应。miRNA 模拟物和 miRNA 沉默分子的出现使人们能够调节肿瘤中的 miRNA 表达，表明 miRNA 可以有效地用作治疗剂。这篇综述将重点介绍那些为将 miRNA 用作患者“量身定制”的抗癌药物提供依据的发现。
Zotero 插件